Sunrise Group, a pioneer in medical device innovation and sleep care, today announced results from the SUNSAS clinical study, now published in The Lancet Regional Health – Europe, a leading ...
Led by researchers at NDORMS as part of the Data Analysis and Real World Interrogation Network (DARWIN EU) initiative, a new ...
Whole-blood transfusion has recently gained favor in the management of severe hemorrhage; however, data from large clinical trials evaluating its clinical effectiveness and safety are lacking. We ...
There was some evidence that cannabinoids can reduce symptoms of cannabis use disorder, insomnia, tic or Tourette's syndrome, and autism spectrum disorder, but the quality of this evidence was ...
The 2026 European Association of Urology (EAU) annual meeting featured a late-breaking abstracts session and a presentation ...
Morning Overview on MSN
Trial: Sulthiame pill cut sleep apnea breathing interruptions by 50%
A once-daily pill called sulthiame cut breathing interruptions during sleep by up to 47 percent in adults with obstructive ...
Utility of the 70-Gene MammaPrint Assay for Prediction of Benefit From Extended Letrozole Therapy in the NRG Oncology/NSABP B-42 Trial Patients with advanced lung cancer reporting at least moderate ...
Malaria control and elimination is threatened by the spread of insecticide resistance and behavioral adaptation of vectors. Whether mass administration of ivermectin, a broad-spectrum antiparasitic ...
VIENNA — Tirzepatide was associated with improvements in body weight and body composition, and with lower insulin doses, in the first-ever randomized controlled trial (RCT) of the drug in people with ...
Hand-foot syndrome (HFS) is a dose-limiting side effect of capecitabine. Celecoxib prevents HFS by inhibiting cyclooxygenase-2 (COX-2) that is upregulated because of the underlying associated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results